Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

Trial Profile

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enobosarm (Primary) ; Semaglutide (Primary)
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Acronyms QUALITY
  • Sponsors Veru Healthcare

Most Recent Events

  • 24 Jun 2025 According to Veru Healthcare Media Release, the company looks forward to report the full Phase 2b QUALITY and Maintenance Extension clinical trial efficacy and safety data at future leading scientific conferences and in publications.
  • 24 Jun 2025 Positive topline results presented in the Veru Healthcare Media Release.
  • 28 May 2025 Topline results presented in a Verus Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top